esgamda 25 mg/ml otopina za injekciju/infuziju
makpharm d.o.o., trnjanska cesta 37/1, zagreb, hrvatska - esketaminklorid - otopina za injekciju / infuziju - urbroj: 1 ml otopine za injekciju/infuziju sadrži 25 mg esketamina, u obliku esketaminklorida
esgamda 5 mg/ml otopina za injekciju/infuziju
makpharm d.o.o., trnjanska cesta 37/1, zagreb, hrvatska - esketaminklorid - otopina za injekciju / infuziju - urbroj: 1 ml otopine za injekciju/infuziju sadrži 5 mg esketamina u obliku esketaminklorida
venclyxto
abbvie deutschland gmbh co. kg - venetoclax - leukemija, limfocitna, kronična, b-stanica - antineoplastična sredstva - venclyxto in combination with obinutuzumab is indicated for the treatment of adult patients with previously untreated chronic lymphocytic leukaemia (cll) (see section 5. venclyxto in combination with rituximab is indicated for the treatment of adult patients with cll who have received at least one prior therapy. venclyxto monotherapy is indicated for the treatment of cll:- in the presence of 17p deletion or tp53 mutation in adult patients who are unsuitable for or have failed a b cell receptor pathway inhibitor, or- in the absence of 17p deletion or tp53 mutation in adult patients who have failed both chemoimmunotherapy and a b-cell receptor pathway inhibitor. venclyxto in combination with a hypomethylating agent is indicated for the treatment of adult patients with newly diagnosed acute myeloid leukaemia (aml) who are ineligible for intensive chemotherapy.
enhertu
daiichi sankyo europe gmbh - trastuzumab deruxtecan - neoplazme dojki - antineoplastična sredstva - breast cancerher2-positive breast cancerenhertu as monotherapy is indicated for the treatment of adult patients with unresectable or metastatic her2-positive breast cancer who have received one or more prior anti-her2-based regimens. her2-low breast cancerenhertu as monotherapy is indicated for the treatment of adult patients with unresectable or metastatic her2-low breast cancer who have received prior chemotherapy in the metastatic setting or developed disease recurrence during or within 6 months of completing adjuvant chemotherapy (see section 4. non-small cell lung cancer (nsclc)enhertu as monotherapy is indicated for the treatment of adult patients with advanced nsclc whose tumours have an activating her2 (erbb2) mutation and who require systemic therapy following platinum-based chemotherapy with or without immunotherapy. gastric cancerenhertu as monotherapy is indicated for the treatment of adult patients with advanced her2-positive gastric or gastroesophageal junction (gej) adenocarcinoma who have received a prior trastuzumab-based regimen.
onivyde pegylated liposomal (previously known as onivyde)
les laboratoires servier - irinotecan anhydrous free-base - neoplazme gušterače - antineoplastična sredstva - liječenje metastatskog adenokarcinoma gušterače, u kombinaciji s 5 fluorouracil (5 fu) i leucovorin (lv), u odraslih bolesnika napredovala nakon gemcitabinom osnovu terapije.
berlithion 600 mg koncentrat za otopinu za infuziju
berlin-chemie menarini hrvatska d.o.o., horvatova 80a, zagreb, hrvatska - tioktatna kiselina - koncentrat za otopinu za infuziju - 600 mg - urbroj: 1 ml koncentrata za otopinu za infuziju sadrži 25 mg tioktatne kiseline
flexid 5 mg/ml otopina za infuziju
sandoz d.o.o., maksimirska 120, zagreb, hrvatska - levofloksacin hemihidrat - otopina za infuziju - 5 mg/ml - urbroj: 1 ml otopine za infuziju sadrži 5 mg levofloksacina (u obliku levofloksacin hemihidrata)
fludarabin accord 25 mg/ml koncentrat za otopinu za injekciju ili infuziju
accord healthcare polska sp. z o.o., ul. tasmowa 7, mazowieckie, varšava, poljska - fludarabinfosfat - koncentrat za otopinu za injekciju/infuziju - 25 mg/ml - urbroj: svaki ml sadrži 25 mg fludarabinfosfata
fludarabin pliva 25 mg/ml koncentrat za otopinu za injekciju/infuziju
pliva hrvatska d.o.o., prilaz baruna filipovića 25, zagreb, hrvatska - fludarabinfosfat - koncentrat za otopinu za injekciju / infuziju - 25 mg/ml - urbroj: bočica s 2 ml koncentrata za otopinu za injekciju/infuziju sadrži 50 mg fludarabinfosfata
sindarabin 50 mg prašak za otopinu za injekciju/infuziju
actavis group ptc ehf., reykjavikurvegur 76-78, hafnarfjordur, island - fludarabinfosfat - prašak za otopinu za injekciju/infuziju - 50 mg/bočici - urbroj: svaka bočica sadrži 50 mg fludarabinfosfata; 1 ml pripremljene otopine sadrži 25 mg fludarabinfosfata